Sun Pharma has reported encouraging mid-to-late stage clinical results for its cancer therapy UNLOXCYT (cosibelimab-ipdl).

 

In a large expansion cohort of 64 patients with locally advanced cutaneous squamous cell carcinoma (laCSCC), nearly half of patients responded to treatment, with an objective response rate of 50%. 

 

This included 17 patients (27%) achieving a complete response and 15 (23%) showing a partial response. Importantly, the median duration of response was not yet reached after a median follow-up of 31 months, suggesting sustained benefit over time.

 

"These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC, which is associated with long-term clinical outcomes. The durability of these responses, a primary therapeutic objective, was achieved alongside a manageable safety profile,” said Rahul Ladwa, Medical Oncologist at the Princess Alexandra Hospital and Greenslopes Private Hospital.

 

The safety profile remained broadly consistent with earlier findings. While treatment-related side effects were common, severe immune-related complications were rare.

 

“The findings from this large cohort of patients are impressive from both an efficacy and tolerability perspective. Patients with laCSCC are older and have many comorbidities, so we need treatment options that are both efficacious and well tolerated, so patients remain on therapy and experience meaningful benefit,” said Emily Ruiz, Associate Professor of Dermatology, Harvard Medical School.